← ANALYST RATINGS · TIPRANKS

Amylyx Pharmaceuticals Inc (AMLX): analyst forecast and price target

$26.34 −4.74% close 16.10.26 · market cap $3.4B · Healthcare · Biotechnology IWM 0.10%
Price targets and ratings of

Analyst consensus

Strong Buy

7 Buy0 Hold0 Sell

Ratings of 7 analysts in the last 3 months · top analysts only

12-month forecast

$46.00+74.6% upside

Based on 7 price targets given in the last 3 months, the average target is $46.00, the highest $57.00, the lowest $39.00. The average is +74.6% from the last price of $26.34.

$20.00$40.00Jan 26AprJulOctJan 27AprJulOctHigh$57.00Average$46.00Low$39.00
Highest target $57.00 Average target $46.00 Lowest target $39.00
AnalystFirmPrice target RatingUpsideAction Date Move vs SPY
Geoff Meacham★★★★★★★★★★#407 · hits 60% · avg +15.3% Citi $32.00 → $39.00+21.9% Buy +48.1% Reiterated 15.10.26on TipRanks 05:55 +2.0%next day −3.6%
James Condulis★★★★★★★★★★#3810 · hits 56% · avg +8.9% Stifel Nicolaus $45.00 Buy +70.8% Reiterated 01.10.26on TipRanks 10:15 −3.7%next day −1.8% · 5 days −4.4%
Seamus Fernandez★★★★★★★★★★#129 · hits 66% · avg +30.6% Guggenheim $55.00 → $57.00+3.6% Buy +116.4% Assigned 26.08.26on TipRanks Aug 27 07:10 −1.0%next day −0.4% · 5 days −6.9%
Rami Katkhuda★★★★★★★★★★#297 · hits 55% · avg +31.7% LifeSci Capital $24.00 → $44.00+83.3% Buy +67.0% Reiterated 22.08.26on TipRanks 15:30 −1.0%next day −2.1% · 5 days −12.0%
Andrew Fein★★★★★★★★★★#267 · hits 52% · avg +23.7% H.C. Wainwright $34.00 → $55.00+61.8% Buy +108.8% Reiterated 20.08.26on TipRanks Aug 18 12:25 +64.5%next day +9.7% · 5 days +6.9%
Geoff Meacham★★★★★★★★★★#407 · hits 60% · avg +15.3% Citi $26.00 → $32.00+23.1% Buy +21.5% Reiterated 19.08.26on TipRanks Aug 18 10:17 +64.5%next day +9.7% · 5 days +6.9%
Graig Suvannavejh★★★★★★★★★★#381 · hits 48% · avg +21.6% Mizuho Securities $30.00 → $42.00+40.0% Buy +59.5% Reiterated 19.08.26on TipRanks Aug 17 06:32 −0.5%next day +64.5% · 5 days +79.2%
Joseph Thome★★★★★★★★★★#320 · hits 57% · avg +24.8% TD Cowen — Buy — Reiterated 18.08.26on TipRanks Aug 19 09:40 +64.5%next day +9.7% · 5 days +6.9%
Jason Gerberry★★★★★★★★★★#184 · hits 63% · avg +21.5% Bank of America Securities $39.00 Buy +48.1% Reiterated 18.08.26on TipRanks Aug 19 04:45 +64.5%next day +9.7% · 5 days +6.9%
Christopher Chen★★★★★★★★★★#5006 · hits 100% · avg +66.9% Robert W. Baird $28.00 → $52.00+85.7% Buy +97.4% Reiterated 18.08.26on TipRanks 15:10 +64.5%next day +9.7% · 5 days +6.9%
James Condulis★★★★★★★★★★#3810 · hits 56% · avg +8.9% Stifel Nicolaus — Buy — Reiterated 18.08.26on TipRanks 10:17 +64.5%next day +9.7% · 5 days +6.9%
Corinne Johnson★★★★★★★★★★#1634 · hits 55% · avg +11.6% Goldman Sachs $22.00 → $23.00+4.5% Buy −12.7% Reiterated 18.06.26on TipRanks 08:10 +1.7%next day +4.2% · 5 days +15.9%

Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst

Best analysts covering Amylyx Pharmaceuticals Inc

TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.

Most accurate

3 months Andrew Fein★★★★★★★★★★H.C. Wainwright · #267
Hits 52%257 of 494 Average return +23.7%
1 year Andrew Fein★★★★★★★★★★H.C. Wainwright · #267
Hits 52%257 of 494 Average return +23.7%
2 years Andrew Fein★★★★★★★★★★H.C. Wainwright · #267
Hits 52%257 of 494 Average return +23.7%

Most profitable

3 months Andrew Fein★★★★★★★★★★H.C. Wainwright · #267
Hits 52%257 of 494 Average return +23.7%
1 year Andrew Fein★★★★★★★★★★H.C. Wainwright · #267
Hits 52%257 of 494 Average return +23.7%
2 years Andrew Fein★★★★★★★★★★H.C. Wainwright · #267
Hits 52%257 of 494 Average return +23.7%

How the average price target moved

The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $45.75 at a price of $29.10 (+57.2%); now: $46.62 at $26.34 (+77.0%).

$30.00$40.00Sep 15Oct 1Oct 15Top analysts$46.00Average target$46.62Price$26.34

PriceAverage targetTop analysts’ target

Recommendation trend · top analysts

01020511Oct 2558Nov59Dec75Jan 2665Feb138Mar1110Apr1511May107Jun106Jul715Aug314Sep213Oct

Strong BuyBuyHoldSell

Rating05.2606.2607.2608.2609.2610.26
Strong Buy151010732
Buy1176151413
Hold000000
Sell000000

Earnings and sales forecast

Next report: 05.11.26 (Q3 2026, date not confirmed)

Earnings per share

Next quarter’s EPS estimate — $-0.38 (from $-0.43 to $-0.31). Last quarter: $-0.39.

Sales

Next quarter’s sales estimate — $0M (from $0M to $0M). Last quarter: $0M.

Best top-analyst consensus in the sector · Healthcare

AXGNAxoGen
MDWDMediwound
OCULOcular Therapeutix
OVIDOvid Therapeutics
ZYMEZymeworks
About Amylyx Pharmaceuticals Inc
  • CEO: Joshua Cohen
  • Employees: 136
  • 55 Cambridge Parkway, Cambridge, MA, 02142, US
  • amylyx.com

Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.

Data from the stock’s TipRanks forecast page, read 24 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗